Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Date:8/19/2007

SAN DIEGO, Aug. 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today unaudited financial results for the second quarter and six months ended June 30, 2007. Cadence reported a net loss for the second quarter of 2007 of $14.9 million, or $0.52 per share, compared to a net loss of $6.2 million, or $4.92 per share, in the second quarter of 2006. For the six months ended June 30, 2007, the company reported a net loss of $24.5 million, or $0.86 per share, compared to a net loss of $35.4 million, or $28.50 per share for the six months ended June 30, 2006.

As of June 30, 2007, Cadence held cash and cash equivalents of $66.9 million.

"We remain keenly focused on executing the development programs for our two Phase III product candidates, intravenous acetaminophen and Omigard(TM)," said Ted Schroeder, Cadence's President and Chief Executive Officer. "As a result, we are on track to meet our clinical development and pre-commercialization manufacturing objectives for both product candidates. In particular, we are pleased with the recent execution of a development and supply agreement for IV acetaminophen with Baxter Healthcare, a leading global contract manufacturer, which we believe will position us to meet the anticipated demand for this important product candidate upon commercialization and for several years thereafter."

Financial Results

Total operating expenses for the second quarter of 2007 were $15.7 million, compared to $6.6 million for the second quarter of 2006. The increase in operating expenses was p
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Francisco, CA (PRWEB) , ... August 04, 2015 , ... ... difference by inviting a diverse selection of entrepreneurs from across the United States to ... CEO Jessica Richman is honored to be chosen to be among the attendees. , ...
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Halozyme ... Quarterly Update Conference Call for the second quarter 2015 ... p.m. PT. Dr. Helen Torley , president and ... same date post-market, Halozyme will release financial results for ... be webcast live through the "Investors" section of Halozyme,s ...
(Date:8/3/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic and Dental sectors of healthcare, announced today that ... Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Nine field days to promote practices that ... by the Soil Health Partnership , the field days will demonstrate how changing ... increasing farm productivity and income. , Brent Bible has practiced no-till farming and planted ...
Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3
... Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results ... , , ... quarter over quarter growth in product sales, driven primarily by our most ... CEO of Angiotech. "In addition, we are encouraged by sales trends for ...
... July 29 Mylan Inc. (Nasdaq: MYL ) today ... in aggregate principal amount of senior notes through a reopening of ... The notes are being offered as additional notes under an existing ... amount of Senior Notes due 2020 on May 19, 2010 ...
... TAI,AN, China , July ... CBPO ) ("China Biologic" or the "Company"), ... the People,s Republic of,China ("PRC"), operating through ... Ltd. ("Taibang") and Guiyang Dalin,Biologic Technologies Co., Ltd. ...
Cached Biology Technology:Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 28Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 29Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 30Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 31Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 32Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010 33Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 2Mylan Announces Proposed Add-On Private Placement of its Senior Notes Due 2020 3China Biologic Products to Attend Canaccord Genuity 30th Annual Growth Conference 2
(Date:7/31/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD ... to advance crypto-currencies such as Bitcoin into the consumer ... way to manage all payments.  The ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Rochester finds that there is no single advanced area of ... beyond those of any other animal species. Instead, humans rely ... different primitive tasks, in order to make sense of a ... a given sentence, the brain will activate a certain set ...
... , an internationally recognized expert at the University of ... been chosen by the U.S. Department of State to ... Miller is one of only ten persons selected for ... rigorous selection process, are highly accomplished in fields of ...
... in a computerized microworld by scientists at Arizona State ... show how common-pool resources such as fisheries, forests, ... effectively by self-organized user groups under certain conditions. ... Science . "We use different experiments with ...
Cached Biology News:Sign language study shows multiple brain regions wired for language 2Sign language study shows multiple brain regions wired for language 3US Department of State names UCR entomologist a Jefferson Science Fellow 2US Department of State names UCR entomologist a Jefferson Science Fellow 3Communication trumps penalties in new study of social-ecological systems 2Communication trumps penalties in new study of social-ecological systems 3
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
...
... DNA quantitation kit is used to quantitate double-stranded ... of RNA or protein. With this kit, DNA ... be detected with a VersaFluor or other fluorometer. ... 10 ng per ml to 5 micrograms per ...
... colony stimulating factors for assays of mouse ... and fetal liver. Suitable for the ... CFU-GEMM when added to methylcellulose at a ... erythropoietin. Will also support growth of ...
Biology Products: